Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Covington
Federal Trade Commission
McKinsey
Johnson and Johnson
Cantor Fitzgerald
Julphar
Chinese Patent Office
Colorcon

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VALTREX

« Back to Dashboard

Clinical Trials for Valtrex

Trial ID Title Status Sponsor Phase Summary
NCT00005663 A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients Unknown status Glaxo Wellcome Phase 3 The purpose of this study is to see if valacyclovir (Valtrex) is a safe and effective treatment for ano-genital HSV infections (herpes simplex virus infections of the anus and external genitals) in HIV-infected patients.
NCT00038831 Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS Completed M.D. Anderson Cancer Center Phase 1/Phase 2 The goal of this clinical research study is to find the highest safe dose of Mylotarg that can be combined with chemotherapy in patients receiving allogeneic bone marrow transplantation. Researchers will study the effects of this treatment combination on patients with high-risk acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome. Primary Objective: 1. To determine the safety and maximum tolerated dose of Mylotarg as part of a reduced-intensity preparative regimen patients undergoing related, mismatched-related or matched unrelated donor transplantation. Secondary Objectives: 1. To evaluate response rates, engraftment kinetics and degree of chimerism achievable with this strategy. 2. To evaluate the incidence and severity of GVHD in this population 3. To evaluate disease-free and overall survival and relapse rates.
NCT00116844 VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies. Completed GlaxoSmithKline Phase 4 Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.
NCT00161434 A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons Completed GlaxoSmithKline Phase 4 The primary objective of this research study is to assess if daily valacyclovir therapy for suppression of HSV-2 reactivation is associated with a decrease in mucosal HIV shedding in individuals co-infected with both HSV-2 and HIV.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Valtrex

Condition Name

Condition Name for Valtrex
Intervention Trials
Healthy 9
Herpes Simplex 6
Chronic Lymphocytic Leukemia 6
HIV Infections 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Valtrex
Intervention Trials
Herpes Simplex 9
Leukemia 7
HIV Infections 7
Leukemia, Lymphoid 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Valtrex

Trials by Country

Trials by Country for Valtrex
Location Trials
United States 96
Canada 17
India 4
Germany 1
Kenya 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Valtrex
Location Trials
Texas 20
California 6
Washington 6
Indiana 5
Florida 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Valtrex

Clinical Trial Phase

Clinical Trial Phase for Valtrex
Clinical Trial Phase Trials
Phase 4 7
Phase 3 6
Phase 2 18
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Valtrex
Clinical Trial Phase Trials
Completed 31
Recruiting 5
Active, not recruiting 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Valtrex

Sponsor Name

Sponsor Name for Valtrex
Sponsor Trials
M.D. Anderson Cancer Center 12
GlaxoSmithKline 7
University of Washington 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Valtrex
Sponsor Trials
Other 35
Industry 35
NIH 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Cerilliant
Fuji
Medtronic
AstraZeneca
Julphar
Farmers Insurance
Healthtrust
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.